Related Experiment Videos
Protective effect of vaccination against Mycoplasma pulmonis respiratory disease in rats
Abstract:
Intravenous vaccination of rats with either viable or Formalin-inactivated Mycoplasma pulmonis reduced the incidence and severity of lower respiratory tract lesions after intranasal challenge with viable organisms. Intranasal vaccination with killed organisms reduced the severity of rhinitis, but did not affect lesions in any other region of the respiratory tract. The maximum protection against upper tract lesions (rhinitis, otitis, and laryngotracheitis) was provided by intravenous immunization with viable organisms. Dual vaccination (intraperitoneal plus intranasal) with killed organisms provided no significant protection in any segment of the tract. However, these ineffective vaccine regimens did not potentiate the lesions. These results conclusively demonstrate that vaccination of rats against mycoplasma respiratory disease is feasible and also suggest that systemic vaccination may provide greater protection for the lungs than intranasal vaccination, at least when equivalent antigen doses are used.
Insights
Intravenous vaccination of rats against Mycoplasma pulmonis respiratory disease is feasible. Systemic vaccination with viable organisms offered the most protection against respiratory lesions in rats.
Area of Science:
- Veterinary immunology
- Mycoplasma research
- Respiratory disease models
Background:
- Mycoplasma pulmonis is a common cause of respiratory disease in rats.
- Effective vaccination strategies are needed to prevent Mycoplasma-induced respiratory illness.
Purpose of the Study:
- To evaluate the efficacy of different vaccination routes and antigen preparations against Mycoplasma pulmonis respiratory disease in rats.
- To compare the protective effects of systemic versus mucosal vaccination.
Main Methods:
- Rats were vaccinated intravenously or intranasally with viable or formalin-inactivated Mycoplasma pulmonis.
- Vaccinated rats were challenged intranasally with viable Mycoplasma pulmonis.
- Respiratory tracts were assessed for lesions.
Main Results:
- Intravenous vaccination with viable or inactivated Mycoplasma pulmonis reduced lower respiratory tract lesions.
- Intranasal vaccination with inactivated organisms only reduced rhinitis severity.
- Intravenous vaccination with viable organisms provided maximum protection against upper respiratory tract lesions.
Conclusions:
- Vaccination against Mycoplasma pulmonis respiratory disease in rats is feasible.
- Systemic vaccination, particularly with viable organisms, appears more effective than intranasal vaccination for protecting the lungs.